ARTICLE | Emerging Company Profile

Artios: Probing DNA Damage

How Artios is attacking a different DNA damage response pathway than PARP

January 11, 2019 9:35 PM UTC

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to the clinic.

Artios is exploring synthetic lethal targets outside of homologous recombination, the standard repair pathway within which PARP works...